Novakand Pharma AB (publ) (STO:NOVKAN)
Sweden · Delayed Price · Currency is SEK 0.1400
+0.0130 (10.24%)
Jan 21, 2026, 5:29 PM CET
Novakand Pharma AB Company Description
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally.
The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer.
It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.
The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025.
Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Novakand Pharma AB (publ)
| Country | Sweden |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Peter Selin |
Contact Details
Address: Karolinska Institutet Science Park Solna, 171 65 Sweden | |
| Phone | 46 8 50 12 60 80 |
| Website | novakand.com |
Stock Details
| Ticker Symbol | NOVKAN |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015658570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Selin | Chief Executive Officer |
| Dr. Thomas Olin Ph.D. | Senior Scientific Advisor and Director |
| Maria Sahiberg | Vice President of Regulatory Affairs and Compliance |
| Johan Schultz | Vice President of Research & Development Operation |